The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) after failure or intolerance of first-line chemotherapy.
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; Regeneron; Sanofi; TRACON Pharma
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); TRACON Pharma (Inst)
 
William M. Garrett
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Jason Clark
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Kimberli J. Brill
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Fitzroy W. Dawkins
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Manuel Hidalgo
No Relationships to Disclose
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)